Global Neoantigen Targeted Therapy Market Growth (Status and Outlook) 2023-2029

Global Neoantigen Targeted Therapy Market Growth (Status and Outlook) 2023-2029

The global Neoantigen Targeted Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Rising prevalence of malignancies and colon cancer, patient preference for targeted therapy, and increased risk of ovarian cancer among women are key factors for increasing market revenue.

Neoantigen therapy is mainly through high-throughput gene sequencing and data analysis to discover individualized numerous somatic mutations in the patient's tumor, screen out mutations that may become neoantigens as targets, and load them on antigen-producing cells (APCs), thereby It has the effect of activating T cells to recognize a variety of new antigens, and then kill tumors.

LPI (LP Information)' newest research report, the “Neoantigen Targeted Therapy Industry Forecast” looks at past sales and reviews total world Neoantigen Targeted Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Neoantigen Targeted Therapy sales for 2023 through 2029. With Neoantigen Targeted Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neoantigen Targeted Therapy industry.

This Insight Report provides a comprehensive analysis of the global Neoantigen Targeted Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neoantigen Targeted Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neoantigen Targeted Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neoantigen Targeted Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neoantigen Targeted Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Neoantigen Targeted Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Off-the-shelf Neoantigen
Personalized Neoantigen

Segmentation by application
Colorectal Cancer
Renal Cell Carcinoma
Non-Small Cell Lung cancer
Bone Cancer
Gynecological Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BioNTech SE
Gritstone Bio
Genocea Biosciences
Moderna
Agenus
Immatics
Advaxis
Precision Biologics
Gilead Sciences
Cellular Biomedicine Group
Achilles Therapeutics
Merck and Co
Beijing Kati Medical Technology

Please note: The report will take approximately 2 business days to prepare and deliver.